Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines

NEXT STORY
Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
PREV STORY
Atreca Announces Appointment of Dr. Stacey Ma and Stephen R. Brady to its Board of Directors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

PositiveID Completes Development of its Caregiver Thermometer with Bluetooth

DELRAY BEACH, Fla., June 22, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (OTCQB:PSID), a life ...

author_avatar
NASDAQ Market News

Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results

author_avatar
NASDAQ Market News

FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years

author_avatar
NASDAQ Market News